Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
37,883,682

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

Pre-Market: $28.43 +0.13 (0.46%) 9:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies

Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.

Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt

Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

Exelixis (EXEL) Amends Agreement With Iconic Therapeutics

Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.

Lilly (LLY) Inks Deal for Multiple Neurologic Indications

Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug

FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.

Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc

AbbVie, Inc. and Pfizer Inc are highlighted in this investment idea article.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $54.84, marking a -1.42% move from the previous day.

Moderna (MRNA) Begins Dosing in Study on Vaccine Against EBV

Moderna (MRNA) doses the first participant in a phase I study evaluating its Epstein-Barr virus vaccine candidate, mRNA-1189.

4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Pfizer and BioNTech to Make mRNA-Based Shingles Vaccine

Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.

Company News for Jan 6, 2022

Companies In The News Are: PFE, LULU, NKE, T, VZ.

Sweta Killa headshot

5 Small-Cap ETFs to Profit From the January Effect

After registering double-digit annual growth, Wall Street is poised to gain from the historical trend of January Effect.

Best Growth Stocks to Buy for January 5th

ABG, APO, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 5, 2022

AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug

AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.

Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?

Style Box ETF report for USMC

The Zacks Analyst Blog Highlights: Meta Platforms, Inc., Bank of America Corporation, Mastercard Inc., Pfizer Inc. and Medtronic plc

Meta Platforms, Inc., Bank of America Corporation and Mastercard Inc., Pfizer Inc. and Medtronic plc are highlighted in this analyst blog.

Sheraz Mian headshot

Top Stock Reports for Meta Platforms, Bank of America & Mastercard

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (FB), Bank of America Corporation (BAC), and Mastercard Incorporated (MA).

Here's Why Momentum Investors Will Love Pfizer (PFE)

Does Pfizer (PFE) have what it takes to be a top stock pick for momentum investors? Let's find out.

PFE vs. RHHBY: Which Stock Should Value Investors Buy Now?

PFE vs. RHHBY: Which Stock Is the Better Value Option?

Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.

New Strong Buy Stocks for January 4th

ABG, CNTY, IIJIY, ORAN, and PFE have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2022.

Spero (SPRO) Application for UTI Drug Gets Priority Review

Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.

Best Growth Stocks to Buy for January 4th

ABG, PFE, and APO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 4, 2022